BioNTech's First FDA Filing Looms as Shareholders Face Pivotal Vote

BioNTech plans 2024 FDA submission for its lead oncology drug, Trastuzumab Pamirtecan, as it pivots from COVID-19 vaccines with a €17B liquidity reserve.

BioNTech is on the cusp of a landmark achievement, with plans to submit its first-ever drug for U.S. regulatory approval this year. The candidate, Trastuzumab Pamirtecan, is an antibody-drug conjugate (ADC) targeting advanced endometrial cancer. This milestone arrives as the company prepares for a shareholder meeting that will authorize the financial and structural framework for its expensive strategic pivot away from pandemic-era revenues.

The clinical data supporting this move are compelling. In a Phase 2 trial involving patients previously treated with checkpoint inhibitors, the therapy demonstrated a response rate of approximately 49%. The U.S. Food and Drug Administration has already granted the candidate Breakthrough Therapy designation. A global Phase 3 study is currently underway, directly comparing the ADC to standard chemotherapy.

This push into oncology is capital-intensive. Management forecasts research and development expenses could reach up to €2.5 billion in 2026. The company is advancing nine late-stage efficacy studies in oncology and aims to initiate further programs before year-end. By the end of 2026, BioNTech plans to have 15 Phase 3 trials active and present data from seven advanced programs.

Financing this transition is not an immediate concern, thanks to a formidable war chest. The company entered the year with a liquidity reserve of €17.2 billion. This cushion is vital as the legacy COVID-19 vaccine business winds down. Executives anticipate a revenue decline of about 25% for the year, with sales expected to fall to just over €2 billion.

Investors have responded positively to the strategic shift. The stock recently closed at €87.00, marking a gain of nearly 13% over the past month. Analyst sentiment remains largely bullish, with a majority recommending a buy. The average price target sits around $133, with Bank of America recently raising its target to $130 following the encouraging clinical readouts.

The upcoming weeks are critical for the company's governance and financial structure. On May 5, BioNTech will report its quarterly figures. Ten days later, on May 15, a virtual Annual General Meeting will convene for a series of decisive votes. Shareholders are being asked to approve a capital increase authorization of €129.5 million, equivalent to half of the current share capital.

Concurrently, a domination and profit transfer agreement with subsidiary BioNTech Discovery is on the agenda. This tax-driven maneuver would allow losses at the parent company level—which recorded a net loss of €1.14 billion in 2025—to be offset against profits from the subsidiary.

The supervisory board is also set for a change. Two renowned oncology specialists, Susanne Schaffert and Iris Loew-Friedrich, are slated to join. This expertise is deemed essential for the new strategic direction. Furthermore, the meeting will address the planned succession for the founding duo, who intend to step back from operational roles by year-end.

External factors add another layer of complexity. New U.S. tariffs impose a 15% duty on EU pharmaceuticals, but BioNTech has secured a crucial exemption for antibody-drug conjugates. This classification shelters the very technology at the core of its new cancer pipeline from the additional levy.

While commercial revenue from the oncology portfolio is not expected in 2026, the company is laying the legal, financial, and clinical groundwork for its future. The May 15 shareholder votes will provide the formal mandate for BioNTech's high-stakes bet on cancer therapeutics.